USANA Health Sciences (NYSE:USNA) Upgraded by ValuEngine to Buy

ValuEngine upgraded shares of USANA Health Sciences (NYSE:USNA) from a hold rating to a buy rating in a report published on Tuesday morning, ValuEngine reports.

Other equities analysts have also issued reports about the company. Zacks Investment Research raised USANA Health Sciences from a hold rating to a strong-buy rating and set a $86.00 price objective for the company in a report on Saturday, October 26th. Jefferies Financial Group began coverage on USANA Health Sciences in a research report on Thursday, August 22nd. They issued a hold rating and a $65.00 target price on the stock. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $74.00.

USNA stock opened at $73.11 on Tuesday. The stock has a market cap of $1.58 billion, a PE ratio of 14.17 and a beta of 0.30. The firm’s 50-day simple moving average is $73.21 and its 200 day simple moving average is $70.32. USANA Health Sciences has a fifty-two week low of $58.30 and a fifty-two week high of $125.61.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, October 22nd. The company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $0.22. USANA Health Sciences had a net margin of 9.38% and a return on equity of 27.60%. The firm had revenue of $260.60 million during the quarter, compared to analyst estimates of $256.22 million. During the same period in the previous year, the business posted $1.24 EPS. USANA Health Sciences’s revenue was down 12.2% on a year-over-year basis. On average, analysts expect that USANA Health Sciences will post 3.99 earnings per share for the current fiscal year.

In related news, Director Robert Auciaux sold 4,018 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $71.87, for a total transaction of $288,773.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO G Doug Iiekking sold 1,746 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $75.33, for a total value of $131,526.18. Following the transaction, the chief financial officer now directly owns 2,032 shares of the company’s stock, valued at approximately $153,070.56. The disclosure for this sale can be found here. Insiders sold 8,385 shares of company stock valued at $617,279 in the last ninety days. Corporate insiders own 42.50% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its stake in USANA Health Sciences by 72.6% during the second quarter. BlackRock Inc. now owns 2,302,511 shares of the company’s stock valued at $182,889,000 after buying an additional 968,239 shares in the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of USANA Health Sciences in the 2nd quarter valued at approximately $17,458,000. Schroder Investment Management Group boosted its stake in USANA Health Sciences by 183.1% in the 2nd quarter. Schroder Investment Management Group now owns 212,492 shares of the company’s stock worth $16,878,000 after purchasing an additional 137,430 shares during the period. Wasatch Advisors Inc. boosted its stake in USANA Health Sciences by 127.0% in the 2nd quarter. Wasatch Advisors Inc. now owns 96,447 shares of the company’s stock worth $7,661,000 after purchasing an additional 53,960 shares during the period. Finally, State of New Jersey Common Pension Fund D purchased a new position in USANA Health Sciences during the 3rd quarter worth approximately $2,633,000. 52.87% of the stock is owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Recommended Story: Forex

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.